-
Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use to Rare Blood Vessel Disorder
06 Jul 2025 16:41 GMT
… aneurysms.
Standard treatment for GCA is … inflammation that develops in multiple autoimmune … steroid tapering, treating GCA by … drug has landed additional FDA approvals in ankylosing spondylitis, psoriatic arthritis, non-radiographic axial spondyloarthritis …
-
Immunomodulator Therapeutics Global Market Research 2024-2030 | R&D Investments Fuel Next-Gen Immunomodulator Development Amid Patent Expiry - ResearchAndMarkets.com
04 Jul 2025 10:58 GMT
… , and ankylosing spondylitis, started … treatment discontinuation … Drug Development Trends - I&I
Trial Landscape
Clinical Trial … Pharmaceuticals
Astellas Pharma
Takeda
Chugai Pharma
Mitsubishi Chemical
Sun Pharmaceutical Industries
Shanghai Pharmaceuticals …
-
I have suffered from dizziness for months and my life is in limbo. What is wrong with me? DR SCURR has the chilling answer
07 Jul 2025 17:14 GMT
… steroid, anti-inflammatory medication, used to treat the pain and … neck problems associated with ankylosing spondylitis are not able to … replies: The standard NHS treatment for osteoarthritis of the … an app called Moodivate, developed by a US professor of …
-
Lateral Epicondylitis Treatment Market Report 2025 – Strategic Insights For Companies Seeking Expansion and Growth
03 Jul 2025 16:33 GMT
… non-invasive treatment options, the development of regenerative … , Cleveland Clinic, Chugai Pharmaceutical, Johns Hopkins Medicine, … growth factors, to treat various medical conditions … #47;report/ankylosing-spondylitis-global-market-report
About …
-
Novartis drug flunks phase 3 test in giant cell arteritis
03 Jul 2025 12:53 GMT
… immunology drug Cosentyx has disappointed in a phase 3 trial … likely to develop visual symptoms.
For many years, treatment for GCA … are already approved by the FDA for GCA.
In 2017, … arthritis, and ankylosing spondylitis and has turned the drug into a $6 …
-
Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish
03 Jul 2025 14:21 GMT
… that a late-stage trial evaluating its drug Cosentyx in adults … week steroid taper in the trial. The drug, however, did not demonstrate … to severe plaque psoriasis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa …
-
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
03 Jul 2025 13:15 GMT
… competitive landscape for GCA treatments is evolving. Just in … U.S. Food and Drug Administration (FDA) and the European … psoriasis, psoriatic arthritis, and ankylosing spondylitis.
In other recent news for … . After 24 weeks of treatment with Fabhalta, the Hb …
-
Service Animals — Barking up the Right Tree
04 Jul 2025 18:08 GMT
… form of autoimmune arthritis, ankylosing spondylitis.
Edmondson told me that … others, promote research, develop a national network of … neighbor on command, bringing medication and preventing panic by … tragic.
I have personally developed, from experience, the …
-
Real-World Data Shows Similar Clinical Outcomes in Patients Receiving Biosimilars Following Switch From Reference Product
04 Jul 2025 16:05 GMT
… arthritis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, Crohn … They are biologic medications that are highly … Clinical Success in Treating Inflammatory Conditions after … Amid an Evolving Treatment Landscape. Pharmacy Times. June …
-
Novartis announces top─line results from phase III GCAptAIN study of Cosentyx in giant cell arteritis
04 Jul 2025 03:44 GMT
… M.D., president, development and chief medical officer, … endpoint of the trial is to assess whether … (PsO), ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA … requiring prompt recognition and treatment. Beyond its physical …